title: Selective serotonin re-uptake inhibitors--a review of the side effects in adolescents.
abstract: BACKGROUND
  Selective serotonin re-uptake inhibitors (SSRIs) are prescribed by general practitioners (GPs) for adolescents. GPs' prescribing patterns for SSRIs changed following warnings issued by United Kingdom and United States drug advisory bodies on the use of antidepressants in children and adolescents in 2003 and 2004, respectively. Recent studies shed further light on the safety profile of SSRIs with adolescents.
  
  
  OBJECTIVE
  To provide a narrative review of the physical and psychiatric side effects of SSRIs as reported by adolescents. To provide GPs with practical advice regarding the prevalence and nature of side effects of SSRIs when prescribed for adolescents.
  
  
  CONCLUSIONS
  The research literature suggests that adolescents taking SSRIs are at a small, but increased, risk of suicidal thoughts and behaviours. The prescribing GP needs to be aware of a number of potential side effects and interactions. Monitoring for common physical side effects and possible emerging suicidal ideas and behaviours, especially early in treatment, is recommended.
authors.affiliation: MBBS, MPM, MD, is Consultant Psychiatrist, Unit Head Early in Life, Monash Health Early in Life and Adjunct Senior Lecturer, Monash University, Melbourne, Victoria.
authors.forename: Michael
authors.initials: M
authors.lastname: Gordon
authors.forename: Glenn
authors.initials: G
authors.lastname: Melvin
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000293:Adolescent; D006261:Headache / Q000139:chemically induced; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced*; D009325:Nausea / Q000139:chemically induced; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D059020:Suicidal Ideation; D013406:Suicide, Attempted; D014839:Vomiting / Q000139:chemically induced
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors